Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,393 | 540 | 2,728 |
| Samples | 1,091 | 224 | 828 |
| Peptides | 951 | 163 | 792 |
Function
ANKRD17 · Ankyrin repeat domain 17
The protein encoded by this gene belongs to the family of ankyrin repeat-containing proteins, and contains two distinct arrays of ankyrin repeats in its amino-terminal region, one with 15 ankyrin repeats, and the other with 10 ankyrin repeats. It also contains a nuclear export signal, nuclear localization signal, and a cyclin-binding RXL motif. Localization of this protein to the nucleus has been shown experimentally, and interactions between this protein and cyclin-dependent kinase 2 have been observed. It has been suggested that this protein plays a role in both DNA replication and in both anti-viral and anti-bacterial innate immune pathways. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 927 amino-acid changes on canonical ENST00000358602 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ANKRD17 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ANKRD17 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Endometrial Carcinoma | 12/42 29% | 52/612 8% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Melanoma | 14/210 7% | 99/1899 5% |
| Non-Small Cell Lung Carcinoma | 35/304 12% | 50/1390 4% |
| Chordoma | 0/7 0% | 1/13 8% |
| Colorectal Carcinoma | 27/143 19% | 107/3239 3% |
| Other Solid Cancers | 4/94 4% | 55/1515 4% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 28/810 3% |
| Neuroendocrine Tumour | 16/154 10% | 8/577 1% |
| Gastric Carcinoma | 4/74 5% | 55/1809 3% |
| Burkitts Lymphoma | 6/32 19% | 1/196 1% |
| Bladder Carcinoma | 3/58 5% | 27/956 3% |
| Other Sarcomas | 6/69 9% | 15/699 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Esophageal Squamous Cell Carcinoma | 7/51 14% | 57/2550 2% |
| Biliary Tract Carcinoma | 2/54 4% | 22/950 2% |
| Head and Neck Carcinoma | 1/85 1% | 38/1574 2% |
| Plasma Cell Myeloma | 3/44 7% | 5/305 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Cervical Carcinoma | 2/35 6% | 8/422 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 16/752 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Esophageal Carcinoma | 3/23 13% | 11/769 1% |
| Ovarian Carcinoma | 4/109 4% | 15/998 2% |
| Hepatocellular Carcinoma | 2/46 4% | 33/2210 1% |
| Ewings Sarcoma | 4/63 6% | 1/262 0% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Breast Carcinoma | 8/144 6% | 38/3264 1% |
Mutation Distribution
Where ANKRD17 is mutated · all tissues, split by cell line vs tissue
How many mutations in ANKRD17 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,393 mutations in ANKRD17
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|